The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00303264|
Recruitment Status : Completed
First Posted : March 16, 2006
Last Update Posted : March 5, 2012
"Functional dyspepsia" has been defined loosely as "pain or discomfort centered in the upper abdomen." The symptoms can also include fullness, early satiety, bloating, belching, nausea, retching and vomiting. These symptoms may present with or without the co-existence of symptoms of heartburn or gastroesophageal reflux disease (GERD). Functional dyspepsia is a diagnosis of exclusion in which other disease states, such as ulcer, cancer, etc. are ruled out and the source of the pain is unknown.
The standard of care for most patients presenting with dyspeptic symptoms has been with proton pump inhibitors (PPI), regardless of whether or not the patient's symptoms include acid-related conditions, e.g., heartburn, GERD, etc. Although PPI treatment has yielded some success in these patients, there is a significant population of patients whose dyspeptic symptoms are not adequately treated with PPI's alone.
The purpose of this study is to evaluate the use of dexloxiglumide in the treatment of the symptoms of functional dyspepsia in patients whose dyspeptic symptoms are not being treated adequately with PPI's.
|Condition or disease||Intervention/treatment||Phase|
|Dyspepsia||Drug: dexloxiglumide Drug: Nexium (esomeprazole)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase II Study to Investigate the Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.|
|Study Start Date :||May 2006|
|Primary Completion Date :||August 2007|
|Study Completion Date :||August 2007|
- Change from baseline in (upper GI) pain/discomfort intensity.
- Change from baseline in (upper GI) non-pain symptoms.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00303264
|United States, Missouri|
|For information regarding investigative sites please contact Forest Professional Affairs|
|St. Louis, Missouri, United States, 63045|